Freshfields Bruckhaus Deringer advised Evotec SE on the acquisition of Central Glass Germany GmbH

Freshfields Bruckhaus Deringer advised Evotec SE on the acquisition of Central Glass Germany GmbH

Freshfields Bruckhaus Deringer ('Freshfields') acted as the legal advisors for the publicly listed Evotec SE on the acquisition of Central Glass Germany GmbH from Japanese chemical manufacturing company Central Glass Co. Ltd.

Central Glass Germany is an EU GMP certified contract developer and manufacturer (CDMO) of active pharmaceutical ingredients with a drug substance manufacturing facility in Halle (Westphalia). Evotec SE is a life science company researching, developing and manufacturing highly effective therapeutics and is listed on the TecDAX and MDAX as well as on NASDAQ.

Freshfields was involved in the corporate and tax structuring of the transaction and negotiation of the share purchase agreement as well as on the negotiation of a new long-term lease agreement for the production facility.

The cross-practice Freshfields team was led by Partner Christoph H. Seibt (Lead) and Principal Associate Jil Rollmann (both Global Transactions, Hamburg) and including Partner Niko Schultz-Süchting (Real Estate), Principal Associates: Aljosha Barath (Intellectual Property, Hamburg), Tobias Franz (Tax, Hamburg) and Associates: Vasco Ollero (Global Transactions, Hamburg), Daniel Extra (Real Estate, Hamburg), Jan Kothe (Tax, Hamburg)

Evotec SE's inhouse counsel Christian Dargel also advised the company in the transaction.